Leader
Anti-TNF
: a new dimension in the pharmacotherapy of
the spondyloarthropathies !?
| The first 150 words of the full text of this article appear below. |
 |
Introduction and overview |
|---|
The therapeutic options for treatment of the
spondyloarthropathies (SpA), especially for ankylosing
spondylitis (AS), are limited. Physiotherapy is important and
non-steroidal anti-inflammatory drugs (NSAIDs) provide
significant symptomatic benefit, as has been shown in many studies, and
recently in a six week/one year trial.1 Apart from
sulfasalazine, a disease modifying antirheumatic drug, which many
rheumatologists use to treat patients with peripheral arthritis and
gut disease in early and in active stages of SpA, few innovative
treatments have arisen in the past decades since indometacin was
developed.2 The Cox-2 selective agent rofecoxib, recently
introduced, causes fewer gastric ulcers but is no more effective than
established NSAIDs.3 The efficacy of rofecoxib in
ankylosing spondylitis (AS) has not been studied to date. Up to 20% of
patients with AS do not respond well or at all to NSAIDs.4 Corticosteroids are effective when applied locally
intra-articularly5 but not systemically in most
patients
an interesting difference
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
Xu, Z., Seitz, K., Fasanmade, A., Ford, J., Williamson, P., Xu, W., Davis, H. M., Zhou, H.
(2008). Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis. J Clin Pharmacol
48: 681-695
[Abstract] [Full Text] -
Pipitone, N., Kingsley, G. H., Manzo, A., Scott, D. L., Pitzalis, C.
(2003). Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology (Oxford)
42: 1138-1148
[Abstract] [Full Text] -
Hadi, A., Hickling, P., Brown, M., Al-Nahhas, A.
(2002). Scintigraphic evidence of effect of infliximab on disease activity in ankylosing spondylitis. Rheumatology (Oxford)
41: 114-116
[Full Text] -
Braun, J, Khan, M A, Sieper, J
(2000). Enthesitis and ankylosis in spondyloarthropathy: What is the target of the immune response?. Ann Rheum Dis
59: 985-994
[Full Text] -
Braun, J., Xiang, J., Brandt, J., Maetzel, H., Haibel, H., Wu, P., Kohler, S., Rudwaleit, M., Siegert, S., Radbruch, A., Thiel, A., Sieper, J.
(2000). Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha : first clinical and laboratory experiences. Ann Rheum Dis
59: i85-89
[Full Text]
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Degenerative joint disease
-
Musculoskeletal syndromes
-
Immunology (including allergy)
-
Calcium and bone
-
Inflammatory bowel disease
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
